Wasatch Advisors LP Buys Shares of 92,742 Eton Pharmaceuticals, Inc. $ETON

Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 92,742 shares of the company’s stock, valued at approximately $3,357,000. Wasatch Advisors LP owned 0.34% of Eton Pharmaceuticals as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Deutsche Bank AG grew its stake in shares of Eton Pharmaceuticals by 4.9% in the fourth quarter. Deutsche Bank AG now owns 18,249 shares of the company’s stock valued at $309,000 after buying an additional 850 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of Eton Pharmaceuticals by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 12,421 shares of the company’s stock valued at $210,000 after buying an additional 1,244 shares during the period. State of Wyoming lifted its stake in Eton Pharmaceuticals by 16.4% during the 1st quarter. State of Wyoming now owns 9,498 shares of the company’s stock worth $234,000 after acquiring an additional 1,337 shares in the last quarter. Man Group plc lifted its stake in Eton Pharmaceuticals by 6.0% during the 2nd quarter. Man Group plc now owns 23,754 shares of the company’s stock worth $338,000 after acquiring an additional 1,350 shares in the last quarter. Finally, Quarry LP acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth about $37,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. HC Wainwright lifted their target price on Eton Pharmaceuticals from $57.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group began coverage on shares of Eton Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Zacks Research cut shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Eton Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Eton Pharmaceuticals News Summary

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $65 price target for Eton Pharmaceuticals (ETON). The target implies meaningful upside from recent trading levels and indicates confidence in the company’s longer-term growth prospects.
• Positive Sentiment: The firm expects earnings to strengthen through 2027, forecasting EPS of $0.26 in Q1, $0.30 in Q2, $0.36 in Q3 and $0.35 in Q4. These estimates suggest improving profitability beyond 2026.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The figures appear unreliable or incomplete, so they provide little actionable information about trading sentiment.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to $0.52 from $0.68. Quarterly estimates were also reduced: Q2 EPS to $0.11 from $0.15, Q3 to $0.17 from $0.23 and Q4 to $0.19 from $0.25. The revisions point to weaker-than-previously-expected near-term earnings and may weigh on the shares.
• Negative Sentiment: The updated FY2026 forecast is below the broader consensus estimate of $0.75 per share, increasing the risk of future estimate cuts or earnings-related disappointment.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $41.58 on Thursday. The stock’s 50-day moving average is $38.23 and its two-hundred day moving average is $28.20. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. Eton Pharmaceuticals, Inc. has a 1-year low of $14.27 and a 1-year high of $50.18. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -593.92 and a beta of 0.86.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. Analysts forecast that Eton Pharmaceuticals, Inc. will post 0.67 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider David Krempa sold 19,679 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the sale, the insider owned 25,249 shares of the company’s stock, valued at $794,586.03. This trade represents a 43.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $1,624,000. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 150,000 shares of company stock worth $4,853,921 over the last 90 days. Insiders own 16.49% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.